Cell preparation

Through CD18-positive cell preparation, hematopoietic stem cells expressing specific markers solve the problem of instability in allogeneic cell transplantation, and promote the rebirth of hippocampal neurons, achieving effective in ischemic diseases and neurological decline. treat.

CN118900693APending Publication Date: 2024-11-05FOUND FOR BIOMEDICAL RES & INNOVATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029209.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-23
Filing Date
2023-03-02
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In the treatment of ischemic diseases, there is a mixture of effective and ineffective cells in allogeneic hematopoietic stem cell transplantation, resulting in unstable therapeutic effect, and the reduction of neuron regeneration in the hippocampus is related to various diseases, and the prior art is difficult to effectively promote Tissue and neuron rebirth.

Method used

Develop a cell preparation that promotes cell adhesion, energy supply and cell-to-cell information transmission by selecting CD18-positive cells, preferably hematopoietic stem cells, expressing glucose transporter (Glut1), connexin 43 (Connexin 43) and Jagged1, and promotes cell adhesion, energy supply and cell-to-cell information transmission, and is used to treat deficiency Hemorrhagic diseases and promote neural regeneration in the hippocampus.

Benefits of technology

It has achieved effective treatment of ischemic diseases, promoted the rebirth of neurons in the hippocampus, improved the stability and effectiveness of treatment, and is suitable for the treatment of diseases such as cerebral infarction and myocardial infarction, and helped prevent and treat aging. resulting in decreased neurological function and mental illness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900693A_ABST
    Figure CN118900693A_ABST
Patent Text Reader

Abstract

The invention provides a cell preparation which has an effective treatment effect on ischemic diseases. The cell preparation has CD18 positive cells. The cell preparation can be produced by obtaining a buffy coat from a sample containing hematopoietic stem cells, removing hindering cells that hinder the therapeutic effect from the buffy coat to obtain monocytes, obtaining CD34-positive, i.e., CD34 + monocytes from the monocytes, and obtaining CD34 + CD18 high monocytes that highly express CD18 from the CD34-positive monocytes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a cell preparation and the like for use in treating a disease that can be expected to be treated by promoting tissue regeneration. Background Art

[0002] In the functional recovery of tissues that have been impaired by ischemic diseases, tissue regeneration is crucial. In recent years, it has been clarified that cell transplantation is effective in the functional recovery. Non-patent document 1 states: The administration of bone marrow mononuclear cells obtained by gravity centrifugation for myocardial infarction can regenerate the microvascular network of the heart and improve cardiac function. Non-patent document 2 states: The administration of CD34-positive cells from peripheral blood purified using specific cell surface antigens for limb ischemia can regenerate the microvascular network of the limbs and improve ischemic symptoms. In addition, non-patent document 3 states: The administration of bone marrow mononuclear cells obtained by gravity centrifugation for limb ischemia can regenerate the microvascular network of the limbs and improve ischemic symptoms. Non-patent document 4 states: The administration of CD34-positive cells from umbilical cord blood purified using specific cell surface antigens for cerebral infarction can regenerate the microvascular network of the brain and improve neural function. In addition, non-patent document 5 states: The administration of bone marrow mononuclear cells obtained by gravity centrifugation for cerebral infarction can regenerate the microvascular network of the brain and improve neural function.

[0003] On the other hand, there are still some problems in the treatment of ischemic diseases using autologous hematopoietic stem cells. For example, the systemic state including blood pressure, heart rate, respiratory state, and various physiological functions of patients with ischemic cerebral infarction in the acute phase is unstable. In addition, the patient's level of consciousness is mostly reduced, usually accompanied by difficulty in collecting bone marrow cells. Therefore, in cases where it is difficult for anesthesiologists and hematologists to provide support or in cases with high risks such as worsening of the condition and adverse events caused by autologous bone marrow fluid collection, the above treatment is difficult. As mentioned above, in order to popularize the treatment of ischemic diseases by stem cell infusion, it is believed that the allogeneic hematopoietic stem cells using established collection methods and preparation and storage methods are ideal choices.

[0004] However, when allogeneic hematopoietic stem cells are used to treat ischemic diseases, it is known that cells that show effective therapeutic effects and cells that do not show effective therapeutic effects are mixed together. Non-patent document 6 states that allogeneic hematopoietic stem cell transplantation can cause damage to the microvascular network and worsening symptoms after myocardial infarction. Non-patent document 7 states that allogeneic hematopoietic stem cell transplantation can cause damage to the microvascular network and worsening symptoms after cerebral infarction. In summary, in order to achieve a therapeutic effect through cell transplantation, especially allogeneic cell transplantation, it is necessary to sort cells that show effective therapeutic effects and cells that do not show effective therapeutic effects, and prepare cell preparations by separating beneficial cells or removing harmful cells.

[0005] The importance of new neurons has also been shown in the field of brain nerves. It has been believed that the number of neurons in the adult brain of humans and rodents does not increase, but in recent years it has been found that new neurons are continuously generated in the hippocampus (Non-Patent Documents 8 and 9).

[0006] Newly generated neurons are incorporated into neural networks to function. In learning or enriched environments, the frequency of neuron birth (neurogenesis) in the hippocampus increases.

[0007] However, on the contrary, it is reported that neurogenesis in the hippocampus decreases with aging (non-patent literature 10, 11). According to a research team from the University of Illinois at Chicago, the University of British Columbia, and the Rush University Medical Center, neurogenesis in the hippocampus persists in adults but decreases sharply in the elderly, indicating that neurogenesis is related to cognitive status (non-patent literature 12).

[0008] It is reported that neurogenesis in the brain is reduced in psychiatric diseases such as depression and schizophrenia, indicating that it is involved in the pathology of these diseases. Neurogenesis in the hippocampus is inhibited by stress, which is considered a risk factor for the onset of depression, while conversely, chronic administration of antidepressants promotes neurogenesis (Non-Patent Documents 13, 14).

[0009] It has been reported that neurogenesis in the hippocampus is reduced in Alzheimer's disease, suggesting its involvement in the pathology. Studies using transgenic mice for the amyloid precursor protein gene (APP) closely associated with Alzheimer's disease have shown that amyloid β (Aβ) is involved in the reduction of neurogenesis in the hippocampus (Non-Patent Document 15).

[0010] Therefore, it is suggested that if neurogenesis in the hippocampus can be promoted, it may be possible to develop new treatments to treat the neurological decline, mental illness, and even dementia that accompanies aging.

[0011] Prior art literature

[0012] Non-patent literature

[0013] Non-Patent Document 1: Autologous transplantation of bone marrow mononuclear cells improved heart function after myocardial infarction. Lin et al. Acta Pharmacol Sin 2004 Jul; 25(7):876-886

[0014] Non-Patent Document 2: Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. Kudo et al. Int Angiol. 2003 Dec; 22(4):344-8

[0015] Non-Patent Document 3: Therapeutic Angiogenesis by Autologous Bone-marrow Transplantation in a General Hospital Setting. Taguchi et al. Eur J Vasc Endovasc Surg. 2003 Mar; 25(3):276-8

[0016] Non-Patent Document 4: Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. Taguchi et al. J Clin Invest. 2004 Aug; 114(3):330-8

[0017] Non-Patent Document 5: Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Nakano-Doi et al. Stem Cells. 2010 Jul; 28(7):1292-302

[0018] Non-patent document 6: Anovel sialyl Lewis

[0019] Non-patent document 7: Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons.delZoppo et al.Stroke.1991Oct; 22(10):1276-83

[0020] Non-patent literature 8: Volume reduction in subcortical regions according to severity of Alzheimer's disease. Roh et al. Neurol. 2011. 258: 1013-1020

[0021] Non-patent literature 9: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Hoglinger et al. Nat. Neurosci. 2004. 7: 726-735

[0022] Non-patent literature 10: Hippocampal atrophy in recurrent major depression. Sheline et al. Proc. Natl. Acad. Sci. USA 1996. 93: 3908-3913

[0023] Non-patent literature 11: Neural stem cell proliferation is decreased inschizophrenia, but not in depression. Reif et al. Mol. Psychiatry 2006.11:514-522

[0024] Non-patent literature 12: Human Hippocampal Neurogenesis Persists in Aged Adults and Alzheimer's Disease Patients. Tobin et al. Cell Stem Cell 2019.24,974-982.e1-e3

[0025] Non-patent literature 13: Adult neurogenesis in humans. Bergmann et al. Cold Spring Harb Perspect Biol. 2015 Jul 1; 7(7): a018994.

[0026] Non-patent literature 14: Neurogenesis in the striatum of the adult human brain. Ernst et al. Cell 2014.156,1072-1083

[0027] Non-patent document 15: Comparison of the value of PCNAand Ki-67as markers ofcell proliferation in ameloblastic tumors.Bologna-Molina et al.Med.OralPatol.Oral Cir.Bucal 2013.18,e174-e179 Summary of the invention

[0028] Problems to be solved by the invention

[0029] The present invention has been made in view of the above-mentioned problems, and an object of the present invention is to provide a cell preparation having an effective therapeutic effect on a disease that can be expected to be treated by promoting tissue regeneration.

[0030] Technical solutions to the problem

[0031] The cell preparation according to the present invention is characterized in that the cell preparation contains CD18-positive cells.

[0032] Effects of the Invention

[0033] According to the present invention, a cell preparation having an effective therapeutic effect on ischemic diseases can be obtained. In addition, according to the present invention, neurogenesis in the hippocampus can be effectively promoted. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1This graph compares the therapeutic effects in the presence and absence of clots in umbilical cord blood mononuclear cells.

[0035] Figure 2 This is a diagram comparing the therapeutic effects of heparin treatment and ACD treatment on umbilical cord blood mononuclear cells.

[0036] Figure 3 The graphs show changes in expression of various adhesion factors involved in cell-cell binding before and after heparin treatment.

[0037] Figure 4 It is a graph showing the relationship between the therapeutic effect and CD18 in cord blood mononuclear cells.

[0038] Figure 5 It is a graph showing the relationship between the therapeutic effect and connexin 43 or Glut1.

[0039] Figure 6 The graph shows the changes in CD18 expression in umbilical cord blood mononuclear cells before freezing and after freezing and thawing.

[0040] Figure 7 The figure shows the cell surface marker analysis by FACS. Among the living cells, more than 90% of the cells were CD18 positive (A), and more than 60% of the cells were CX43 positive (B).

[0041] Figure 8 This is a diagram showing that CD34-positive cells express Jagged1.

[0042] Fig. 9 It is a diagram showing that VEGF uptake by HUVEC is promoted by Jagged1-based stimulation.

[0043] Fig.10 It is a figure which shows the quantitative evaluation of the number of newborn neurons in the dentate gyrus of the hippocampus. As a result, it was found that both Nestin-positive cells (A) and DCX-positive cells (B) were statistically significantly increased by the administration of CD18-positive cells. DETAILED DESCRIPTION

[0044] Hereinafter, an embodiment of the present invention will be described in detail with reference to the accompanying drawings. This embodiment is completed to facilitate understanding of the principle of the present invention. The scope of the present invention is not limited to the following embodiment. Other embodiments obtained by those skilled in the art by appropriately replacing the configuration of the following embodiment are also included in the scope of the present invention.

[0045] The cell preparation according to the present invention is characterized by comprising CD18 positive cells. The CD18 positive cells are preferably stem cells.

[0046] (1) Stem cells

[0047] Stem cells are cells that have the ability to differentiate into various cells and the ability to self-replicate, and examples thereof include adult stem cells and pluripotent stem cells.

[0048] Adult stem cells are stem cells that exist in various tissues of the adult body, have not yet completed terminal differentiation, and have a certain degree of multidifferentiation ability. Examples include hematopoietic stem cells, mesenchymal stem cells, neural stem cells, intestinal epithelial stem cells, hair follicle stem cells, pigment stem cells, etc.

[0049] Pluripotent stem cells are cells that have the ability to differentiate into all types of cells that constitute an organism and can continue to proliferate indefinitely while maintaining pluripotency in in vitro culture under appropriate conditions. Examples include embryonic stem cells (ES cells), embryonic germ stem cells (EG cells), germline stem cells (GS cells), and induced pluripotent stem cells (iPS cells).

[0050] In the cell preparation according to the present invention, the stem cells are preferably hematopoietic stem cells.

[0051] Hematopoietic stem cells are cells that have the ability to differentiate into all blood cell lineages and are capable of self-replication while maintaining this ability.

[0052] Hematopoietic stem cells are usually isolated from the above tissues based on the expression of specific surface markers (hematopoietic stem cell specific markers) in the cells. Regarding the expression of the above markers, hematopoietic cells from humans are usually characterized by CD34 positivity. More specifically, hematopoietic stem cells are CD34 positive (+) CD38 negative (-) CD90 positive (+) CD45RA negative (-) cells, preferably CD34 + CD38 - CD90 + CD45RA - CD49f + cell.

[0053] The tissue from which hematopoietic stem cells are derived is not particularly limited as long as the cells are present, but is preferably a hematopoietic tissue, and examples thereof include bone marrow, umbilical cord blood, peripheral blood, and liver.

[0054] CD34 positive cells refer to cells enriched with CD34 positive cells, which can be obtained from samples such as bone marrow, peripheral blood, placenta, umbilical cord blood, etc. according to methods well known in the art, such as by concentrating CD34 positive cells. For example, CD34 fixed beads and cell sorters can be used to concentrate CD34 positive cells. A preferred example of CD34 positive cells is CD34 positive monocytes.

[0055] Although the hematopoietic stem cells of the present invention are allogeneic cells for medical convenience, autologous cells are not excluded. In one embodiment, the hematopoietic stem cells can be prepared from an allogeneic umbilical cord blood sample of the pharmaceutical composition of the present invention, and in another embodiment, the hematopoietic stem cells can be prepared from a stored cell population.

[0056] (2-1)CD18

[0057] CD18 is also called β2 integrin. Integrins are molecules expressed in various cells and play an important role in cell adhesion. Integrins are dimeric cell transmembrane proteins composed of α chains and β chains. There are 24 types of integrins formed by 18 α chains and 8 β chains.

[0058] CD18 is also called leukocyte integrin and is specifically expressed in leukocytes. However, the present inventors focused on the fact that CD18 is expressed in hematopoietic stem cells other than leukocytes, and found that CD18 plays an important role in cell adhesion of hematopoietic stem cells. CD18 is usually unable to bind to ligands, but after activation, a reversible spatial structural change occurs and it becomes able to bind to ligands.

[0059] CD18-positive cells are, for example, a cell population in which the ratio of cells showing CD18-positive reaction when analyzed by flow cytometry is 60% or more, preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more.

[0060] In addition, for example, CD18-positive cells may be a cell population in which the MIF of the CD18 antigen can be maintained at 2 times or more, preferably 3 times or more, and more preferably 4 times or more of the MIF (mean fluorescence intensity) when reacting with an isotype control antibody in flow cytometry.

[0061] (2-2) Glucose transporter (Glut)

[0062] Glucose transporter (Glut) is a membrane protein called a sugar transporter on the cell membrane that is necessary for glucose to pass through biological membranes. Currently, 13 types of Glut (GLUT-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, HMIT) have been reported, but the four molecules of Glut1 to Glut4 belonging to Class I have been explained in detail, and their expression sites and functions are all about 50 kDa, and have a common structure that penetrates the cell membrane 12 times. Type I glucose transporter (Glut1) plays an important role in transporting glucose from the cerebral blood vessels to the brain, and the inventors have found that Glut1 is closely related to the effect expression of hematopoietic stem cells.

[0063] (2-3) Connexin43

[0064] Connexin is a general term for the family of connexin membrane proteins that constitute gap junctions. According to the difference in molecular weight of connexin, more than 12 subtypes have been found. The molecular weight of 26kDa is called connexin 26, and the molecular weight of 43kDa is called connexin 43. In the connexin family, connexin 43 is present in large quantities in central nervous system and myocardial cells. If its amount is reduced, it is speculated that it will cause adverse effects such as arrhythmia. The inventors found that connexin 43 is closely related to the effect expression of hematopoietic stem cells.

[0065] (2-4)Jagged1

[0066] Jagged1 is a ligand of the Notch receptor. The Notch signaling pathway is very important in the transmission of information between cells. The inventors found that Jagged1 is closely related to the effect expression of hematopoietic stem cells.

[0067] (2-5)

[0068] That is, the mechanism by which hematopoietic stem cells promote angiogenesis is a simple cell-cell interaction (interaction between hematopoietic stem cells and damaged vascular endothelial cells) that occurs immediately after cell administration, and does not require the survival, proliferation, and differentiation of transplanted stem cells. If CD18 is expressed, the administered hematopoietic stem cells effectively adhere to vascular endothelial cells. If connexin is expressed, the administered hematopoietic stem cells effectively connect to vascular endothelial cells through gap junctions. If glucose transporter (Glut) is expressed, energy is effectively supplied from glucose-rich hematopoietic stem cells to vascular endothelial cells via gap junctions. If Jagged1 is expressed, intercellular information transmission between the administered hematopoietic stem cells and vascular endothelial cells can be effectively performed.

[0069] Therefore, a cell preparation having excellent therapeutic effects is expected to be a cell preparation characterized by CD18-positive cells, which preferably express glucose transporter Glut (especially preferably Glut1), preferably express connexin (especially preferably Connexin43), and preferably express Jagged1.

[0070] In addition, as described later, the expression intensity of glucose transporter (Glut), which is an indicator of the ability to promote VEGF uptake, is useful as a marker for sorting monocytes with high therapeutic effects. Therefore, a cell preparation that can be expected to have excellent therapeutic effects is a cell preparation characterized by having Glut-positive cells (preferably Glut1-positive cells).

[0071] In addition, as described later, the expression intensity of connexin, which is an indicator of the ability to promote VEGF uptake, is useful as a marker for sorting monocytes with high therapeutic effects. Therefore, a cell preparation that can be expected to have excellent therapeutic effects is a cell preparation characterized by having connexin-positive cells (preferably connexin43-positive cells).

[0072] In addition, as described later, it has been confirmed that the expression of Jagged1 in stem cells is essential for the regeneration-promoting effect. Therefore, a cell preparation characterized by Jagged1-positive cells can be expected to have excellent therapeutic effects.

[0073] (3) Cell preparation

[0074] The cell preparation of the present invention is a cell preparation for treating and / or preventing diseases that can be expected to be treated by tissue regeneration. In this specification, "treatment" includes curing symptoms, improving symptoms and inhibiting the progression of symptoms. On the other hand, "prevention" includes inhibiting the onset of disease and delaying the onset of disease, including not only prevention before the onset of disease, but also prevention of disease recurrence after treatment.

[0075] The cell preparations of the present invention target ischemic diseases, such as cerebral infarction, myocardial infarction, limb ischemia, renal infarction, pulmonary infarction, splenic infarction, intestinal infarction, etc. The cell preparations of the present invention eliminate ischemic diseases by administering stem cells that highly express CD18 to generate microangiogenesis around ischemia, and the target diseases are not limited to the diseases described in the examples.

[0076] When the cell preparation of the present invention is used for cerebral infarction, it is used in any period of the hyperacute phase, acute phase, subacute phase and chronic phase, and is particularly suitable for acute and subacute phases for ischemic diseases with acute onset such as acute myocardial infarction and cerebral infarction. Here, the hyperacute phase is a period within 12 hours after the onset of the disease, which is a period when tissue cell death is likely to be prevented by stent implantation, thrombolytic therapy, thrombus removal, etc. The acute phase is a period within 12 hours to 7 days after the onset of the disease, and the subacute phase is a period within 1 week to 4 weeks after the onset of the disease. The chronic phase is a period of more than one month after the onset of the disease. On the other hand, it can be applied to any period for chronic progressive ischemic diseases such as limb ischemia caused by chronic circulatory disorders.

[0077] The cell preparation of the present invention is also targeted at diseases that can be treated by neurogenesis in the hippocampus. That is, the cell preparation of the present invention is a neurogenesis promoter characterized by having CD18-positive cells and capable of promoting neurogenesis in the hippocampus.

[0078] In recent years, studies have shown that in the hippocampus, a specific brain region, neural stem and precursor cells exist even in the mature stage, and that new neurons are generated through the proliferation and differentiation of these cells. The newly generated neurons play an important role in forming neural networks and participating in memory formation.

[0079] However, aging has been shown to inhibit neurogenesis in the hippocampus, contributing to reduced neurological function in the elderly.

[0080] In addition, stress is considered a risk factor for the onset of mental illnesses such as depression. When animals are subjected to not only physical and mental stress such as restraint stress, but also mental stress such as resident-intruder stress, the number of hippocampal neural stem and precursor cells decreases, indicating that the inhibition of hippocampal neurogenesis may be involved in the etiology of mental illnesses such as depression.

[0081] Neurogenesis in the hippocampus has been reported to be reduced in dementias associated with neurodegenerative diseases, suggesting its involvement in the pathology of these diseases.

[0082] Therefore, by promoting neurogenesis in the hippocampus, it is possible to prevent and / or treat the decrease in neurological function caused by aging, and also to prevent and / or treat diseases associated with neurological dysfunction caused by aging. Furthermore, it is possible to prevent and / or treat dementia associated with neurodegenerative diseases, and also to prevent and / or treat mental illness.

[0083] The hippocampus is located at the bottom of the lateral ventricle below the medial temporal lobe of the brain, and is an indispensable cortical part for the formation of explicit memory such as episodic memory. The dentate gyrus is an appendage of the hippocampus and is considered as a part of the hippocampus in this manual. The dentate gyrus consists of three layers: the central layer is the granule cell layer, the layer directly above is the molecular layer with extremely low cell density, and the layer below is the polymorphic cell layer with sparsely visible cells.

[0084] CD18-positive cells are preferably connexin 43-positive. All tissues and organs of the adult body have various forms of connections between adjacent cells to maintain their homeostasis as tissues. Connexin 43 is an important molecule for gap junctions between cells and is expressed in, for example, osteoblasts, osteocytes, intravascular cells, and nerve cells. The inventors have found that connexin 43-positive cells play an important role in neurogenesis in the hippocampus (especially neurogenesis in the dentate gyrus). Connexin 43-positive cells refer to a cell population that highly expresses connexin 43. The so-called high expression of connexin 43 is not particularly limited, for example, the proportion of cells showing a positive reaction to connexin 43 when analyzed by flow cytometry is 60% or more, preferably 70% or more, more preferably 80% or more, and further preferably 90% or more.

[0085] The administration route of the cell preparation of the present invention is preferably intravenous administration, intra-arterial administration, intra-portal vein administration, or local tissue administration. The number of cells to be administered is not particularly limited and can be appropriately set according to the age, weight, disease, symptoms, and administration method of the target patient. For example, in the case of limb ischemia, the pharmaceutical composition of the present invention is prepared as follows: 10 hematopoietic stem cells are administered. 4 Piece / Kg~10 6 About 10 pieces / Kg, preferably 10 4 pcs / Kg or more, more preferably 5×10 4 pcs / kg or more, more preferably 5×10 5 pcs / Kg or more, 2×10 6 In the case of cerebral infarction, the pharmaceutical composition of the present invention is prepared as follows: based on hematopoietic stem cells, 10 4 Piece / Kg~10 6 About 10 pieces / Kg, preferably 10 4 pcs / Kg or more, more preferably 5×10 4 The total number of cells (monocytes) is about 100 times the value of hematopoietic stem cells mentioned above.

[0086] In the present invention, angiogenesis promoting factors can also be contained. The angiogenesis promoting factors are not particularly limited, and for example, VEGF, angiopoietin, PDGF, TGF-β, FGF, PIGF, matrix metalloproteinases, plasminogen activators, etc. can be used, preferably angiopoietin. Angiopoietin is a glycoprotein growth factor that promotes angiogenesis (vasculogenesis) or angiogenesis (angiogenesis). Angiopoietin includes not only four types of angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3), and angiopoietin 4 (Ang4), but also six angiopoietin-related proteins (ANGPTL: angiopoietin-related protein, or angiopoietin-like protein) as similar proteins.

[0087] When the cell preparation of the present invention is made into an injection preparation, additives commonly used in the art can be appropriately used. As additives, for example, isotonic agents, stabilizers, buffers, preservatives, chelating agents, antioxidants, solubilizing agents, etc. can be mentioned. As isotonic agents, for example, sugars such as glucose, sorbitol, mannitol, sodium chloride, glycerol, propylene glycol, polyethylene glycol, etc. can be mentioned. As stabilizers, for example, sodium sulfite, etc. can be mentioned. As buffers, for example, boric acid buffers, phosphate buffers, citric acid buffers, tartaric acid buffers, acetic acid buffers, etc. can be mentioned. As preservatives, for example, parabens, benzyl alcohol, chlorocresol, phenethyl alcohol, benzethonium chloride, etc. can be mentioned. As chelating agents, for example, sodium edetate, sodium citrate, etc. can be mentioned. As antioxidants, for example, sodium sulfite, sodium bisulfite, sodium ascorbate, sodium thiosulfate, etc. can be mentioned. Examples of the solubilizing agent include dextran, polyvinyl pyrrolidone, sodium benzoate, ethylenediamine, salicylamide, niacinamide, and polyoxyethylene hydrogenated castor oil derivatives.

[0088] (4) Method for producing cell preparations

[0089] The cell preparation containing cells highly expressing CD18 is not particularly limited and can be produced by the following method.

[0090] For example, the method includes the steps of obtaining a buffy coat layer from a sample containing hematopoietic stem cells, obtaining monocytes by removing inhibitory cells that inhibit therapeutic effects from the buffy coat layer, and obtaining CD18high monocytes that highly express CD18 from the monocytes.

[0091] In addition, for example, the method comprises the steps of obtaining a buffy coat from a sample containing hematopoietic stem cells, obtaining monocytes by removing inhibitory cells that inhibit the therapeutic effect from the buffy coat, and obtaining CD34 positive CD34 from the monocytes. + The process of mononuclear cells, and obtaining CD34 cells that highly express CD18 from CD34 positive monocytes + CD18high monocytes.

[0092] In addition, for example, the method includes the steps of selecting a sample containing many CD18-high expressing cells from a plurality of blood samples collected from a plurality of patients, and removing inhibitory cells that inhibit the therapeutic effect from the blood sample.

[0093] For example, the method comprises the steps of increasing CD18 high-expressing cells by allowing cytokines such as TNFα to act on the collected blood sample, and removing inhibitory cells that inhibit the therapeutic effect from the blood sample in which CD18 high-expressing cells have been increased.

[0094] Normally, umbilical cord blood, blood, and bone marrow fluid are easy to coagulate, and therefore heparin is often used as an anticoagulant. However, in the present invention, heparin is not used, but coagulation is inhibited by dilution with physiological saline and a divalent ion chelator.

[0095] As a sample containing hematopoietic stem cells, umbilical cord blood, bone marrow fluid, or peripheral blood samples can be used, and umbilical cord blood samples are preferred.

[0096] Mononuclear cells accumulated in the buffy coat are obtained from the umbilical cord blood sample by density gradient centrifugation. For density gradient centrifugation, for example, commercially available density gradient centrifugation media such as Ficoll (registered trademark) and Percoll (registered trademark) are preferably used.

[0097] The buffy coat may contain inhibitory cells that inhibit the effectiveness of the therapeutic effect of the cell preparation. Therefore, it is desirable to remove the inhibitory cells in the buffy coat. The inhibitory cells in the buffy coat are neutrophils and dead cells.

[0098] In order to remove the obstructive cells in the buffy coat, the obstructive cells are separated by adding PBS in an amount equal to that of the buffy coat to the buffy coat and centrifuging. The centrifugal force used to separate the obstructive cells has an upper limit of, for example, 1000 g, 900 g, 800 g, 700 g, and 600 g, and a lower limit of 500 g or 400 g, for example, in the range of 400 g to 1000 g, 400 g to 900 g, 400 g to 800 g, 400 g to 700 g, and 400 g to 600 g. It is preferably 400 g to 800 g, and more preferably 500 g to 800 g.

[0099] The sediment of the buffy coat after centrifugation becomes a fraction in which neutrophils and dead cells are concentrated in the upper layer and a fraction in which monocytes are concentrated in the lower layer. When the supernatant is removed after centrifugation, the neutrophils and dead cells in the upper layer of the sediment can be selectively removed by gradually leveling the container. Furthermore, in order to remove the neutrophils and dead cells contained in the mononuclear fraction, it is preferred to perform centrifugation under the same conditions and pass through a 40 μm filter.

[0100] Next, hematopoietic stem cells are obtained from the mononuclear cells in the buffy coat. Hematopoietic stem cells are obtained by concentrating CD34-positive cells according to a well-known method. Concentration of CD34-positive cells can be performed using CD34-fixed beads or a cell sorter.

[0101] Next, CD18 positive cells are obtained by enriching the CD34 positive monocytes in the buffy coat. CD18 positive cells can be enriched using CD18 fixed beads and a cell sorter to obtain cells that highly express CD18.

[0102] CD34 + CD18 high Monocytes. It should be noted that CD34 + CD18 high The order is not limited to this embodiment, and cells highly expressing CD18 may be first obtained from the mononuclear cells in the buffy coat, and then CD34-positive cells may be further concentrated therefrom.

[0103] Example

[0104] (1) The influence of agglutination in cord blood mononuclear cell therapy

[0105] In the treatment of cerebral infarction using bone marrow mononuclear cells, it was found that the treatment effect of cerebral infarction was significantly reduced in the batches that formed agglomerates. Therefore, an experiment was conducted to confirm whether the same phenomenon occurred in umbilical cord blood mononuclear cells.

[0106] Mononuclear cells were purified from cord blood without agglutination and cord blood with large agglutination by density gradient (Ficoll-Paque) centrifugation, washed with PBS, and then co-cultured with HUVEC ( Figure 1 ). It should be noted that Figure 1 CBMNC indicates mononuclear cells from human umbilical cord blood.

[0107] The co-culture test was carried out as follows. That is, the umbilical cord blood was gently placed on an equivalent Ficoll-Paque upper layer and centrifuged at 400g for 30 minutes. The accelerator and brake settings of the centrifuge were implemented at the minimum value. The buffy coat was separated from the umbilical cord blood sample after centrifugation, an equivalent amount of PBS containing 10% anticoagulant-citric acid-glucose solution (ACD solution) was added, and centrifuged again at 400g for 5 minutes. The accelerator and brake settings of the centrifuge at this time do not need to be the minimum value. The precipitate of the buffy coat after centrifugation becomes a fraction in which neutrophils and dead cells are concentrated in the upper layer, and a fraction in which monocytes are concentrated in the lower layer. Therefore, when removing the supernatant, the neutrophils and dead cells in the upper layer of the precipitate are selectively removed by gradually leveling the container. Furthermore, in order to remove the neutrophils and dead cells contained in the mononuclear fraction, centrifugation was performed at 400g for 5 minutes and passed through a 40μm filter. Next, HUVECs were cultured in HuMedia-EB2 medium with serum and growth supplements according to the manufacturer's protocol, and then detached and recovered using trypsin. 5 Allophycocyanin (APC)-labeled vascular endothelial growth factor (VEGF, final concentration 3 μg / mL) and the above-mentioned umbilical cord blood mononuclear cells (1×10 6 ) and incubated in a 24-well plate at 37°C and 5% CO2 for 3 hours. The cell mixture was washed twice with phosphate-buffered saline (PBS) and stained with anti-human CD31 antibody labeled with phycoerythrin (PE) (BD Bioscience), anti-human CD45 antibody labeled with FITC (fluorescein isothiocyanate), and 7AAD (7-aminoactinomycin D) purchased from BD Bioscience, and the level of APC-labeled VEGF taken up by vascular endothelial cells (CD31 positive, CD45 negative, and 7AAD negative) was evaluated by FACS Canto II cell analyzer (BD Bioscience). Since the angiogenic vascular endothelial cells take up VEGF from the outside of the cells, the higher the value of the umbilical cord blood, the more strongly it promotes angiogenesis. In other words, it is considered to be umbilical cord blood with a high therapeutic effect on cerebral infarction.

[0108] like Figure 1As shown, in the case of CBNMC without agglomerates, the presence of CBNMC caused the vascular endothelial cells to take up a large amount of VEGF. However, in the case of CBNMC with agglomerates, the vascular endothelial cells hardly took up VEGF even in the presence of CBMNC. This showed that, like the mononuclear cells in the bone marrow, the uptake of VEGF was not strongly promoted in the mononuclear cells in the presence of agglomerates.

[0109] (2) Reduced therapeutic effect due to heparin treatment

[0110] In the co-culture test, PBS prepared so that the final heparin concentration was 2 unit / mL was added instead of PBS containing 10% anticoagulant-citric acid-dextrose solution (ACD solution).

[0111] That is, the umbilical cord blood is gently placed on an equivalent Ficoll-Paque upper layer and centrifuged at 400g for 30 minutes. The accelerator and brake settings of the centrifuge are implemented at the minimum value. The buffy coat is separated from the umbilical cord blood sample after centrifugation, and PBS prepared in a manner to make the final heparin concentration 2unit / mL is mistakenly added, and the buffy coat is centrifuged again at 400g for 5 minutes to precipitate the buffy coat. Furthermore, in order to remove the neutrophils and dead cells contained in the mononuclear fraction, centrifuge at 400g for 5 minutes and pass through a 40μm filter. The above-mentioned co-culture test is performed on the umbilical cord blood mononuclear cells thus obtained.

[0112] In the co-culture experiment using the cord blood mononuclear cells, a decrease in VEGF uptake was observed in the case of heparin treatment compared to the case of adding a conventional ACD solution to PBS, which was equivalent to the case of forming aggregates ( Figure 2 ).

[0113] (3) Discovery of the importance of adhesion factors

[0114] from Figure 2 The results showed that the cell-cell connection between hematopoietic stem cells and HUVEC is important. Therefore, the expression changes of various adhesion factors involved in cell-cell connection in hematopoietic stem cells were compared before and after heparin treatment ( Figure 3 ).

[0115] That is, the umbilical cord blood is placed on an equivalent Ficoll-Paque upper layer and centrifuged at 400g for 30 minutes. The buffy coat is separated from the umbilical cord blood sample after centrifugation, an equivalent amount of PBS containing 10% anticoagulant-citric acid-dextrose solution (ACD solution) is added, and centrifuged again at 400g for 5 minutes. The separation of the buffy coat precipitate is carried out by gradually leveling the container to remove the supernatant, and the precipitate is resuspended in PBS and centrifuged at 400g for 5 minutes, and then passed through a 40μm filter. The mononuclear cell suspension after passing through the filter is divided equally and centrifuged at 400g for 5 minutes. After removing the supernatant, one portion is suspended in PBS and the other portion is suspended in PBS prepared in a manner such that the final heparin concentration is 2unit / mL, and incubated at room temperature for 5 minutes. Next, the cell suspension was washed with PBS and stained with PE (phycoerythrin)-labeled anti-human CD34 antibody (BD Bioscience), 7AAD (7-aminoactinomycin D) (BD Bioscience), FITC (fluoresceinisothiocyanate)-labeled anti-human CD45 antibody (BD Bioscience), and APC (allophycocyanin)-labeled various adhesion factor antibodies [integrin α4 antibody (Beckman Coulter), integrin α5 antibody (Beckman Coulter), CD18 antibody (Beckman Coulter), or CXCR4 antibody (MBL)], and the expression levels of various adhesion factors in hematopoietic stem cells (CD34 positive and 7AAD negative) were evaluated using FACS Canto II cell analyzer (BD Bioscience).

[0116] like Figure 3 As shown, no significant change in the expression of integrin α4, a representative adhesion factor that functions in the homing and cell adhesion of hematopoietic stem cells, was observed due to heparin treatment.

[0117] Adhesion factors whose expression significantly changed due to heparin treatment were integrin α5, CXC chemokine receptor 4 (CXCR4), and CD18. Among these molecules, there were molecules whose expression significantly decreased due to heparin treatment and molecules whose expression hardly decreased. In particular, the adhesion factor whose expression significantly changed due to heparin treatment was CD18.

[0118] (4) Discovery of markers for the selection of monocytes with high therapeutic effects

[0119] As described above, cord blood mononuclear cells that strongly promote VEGF uptake and cord blood mononuclear cells that do not strongly promote VEGF uptake were observed. The relationship between the expression of CD18 in these cord blood hematopoietic stem cells and the ability to promote VEGF uptake was studied, and the results showed that the two were strongly positively correlated ( Figure 4 ).

[0120] That is, the umbilical cord blood was placed on an equivalent Ficoll-Paque upper layer and centrifuged at 400g for 30 minutes. The buffy coat was separated from the centrifuged umbilical cord blood sample, an equivalent amount of PBS containing 10% anticoagulant-citric acid-dextrose solution (ACD solution) was added, and centrifuged again at 400g for 5 minutes. The precipitate of the buffy coat was separated by gradually leveling the container to remove the supernatant. The precipitate was resuspended in PBS, centrifuged at 400g for 5 minutes, then passed through a 40μm filter, and resuspended in PBS. Next, a portion of the suspension was separated and stained with PE-labeled anti-human CD34 antibody, 7AAD, FITC-labeled anti-human CD45 antibody, and APC-labeled CD18 antibody.

[0121] Furthermore, the remaining suspension was used to perform a co-culture test with HUVEC (see (1) above). 5 Allophycocyanin (APC)-labeled vascular endothelial growth factor (VEGF, final concentration 3 μg / mL) and umbilical cord blood mononuclear cells (containing 1×10 4 The co-culture experiment was carried out under the condition of 1:1 CD34 positive cells (cell number).

[0122] Figure 4 The left side shows the difference in VEGF uptake capacity in each co-cultured cord blood HUVEC. Figure 4 The right side shows the correlation between the expression of CD18 in hematopoietic stem cells (CD34 positive and 7AAD negative) and the VEGF uptake capacity of HUVEC in the co-culture experiment. It was found that the expression intensity of CD18, which was discovered as an indicator of the ability to promote VEGF uptake by accidental heparin treatment, is useful as a marker for selecting monocytes with high therapeutic effects.

[0123] In the above experiment, the precipitate of the buffy coat was resuspended in PBS, centrifuged at 400 g for 5 minutes, then passed through a 40 μm filter and resuspended in PBS. Next, a portion of the suspension was taken and stained with PE-labeled anti-human CD34 antibody, 7AAD, FITC-labeled anti-human CD45 antibody, and APC-labeled glucose transporter (Glut1) antibody. Furthermore, the remaining suspension was used to perform a co-culture experiment with HUVEC (see (1) above). 5 Allophycocyanin (APC)-labeled vascular endothelial growth factor (VEGF, final concentration 3 μg / mL) and umbilical cord blood mononuclear cells (containing 1×10 4 The co-culture experiment was carried out under the condition of 1:1 CD34 positive cells (cell number). Figure 5 The right side shows the correlation between the expression of glucose transporter (Glut1) in hematopoietic stem cells (CD34 positive, CD45 positive and 7AAD negative) and the VEGF uptake ability of HUVEC in the co-culture experiment. It was found that the expression intensity of glucose transporter (Glut1), which is an indicator of the ability to promote VEGF uptake, is useful as a marker for selecting monocytes with high therapeutic effects.

[0124] In addition, in the above experiment, the precipitate of the buffy coat was resuspended in PBS, centrifuged at 400g for 5 minutes, then passed through a 40μm filter and resuspended in PBS. Next, a portion of the suspension was taken and stained with PE-labeled anti-human CD34 antibody, 7AAD, FITC-labeled anti-human CD45 antibody, and APC-labeled connexin43 antibody. Furthermore, the remaining suspension was used to perform a co-culture experiment with HUVEC (see (1) above). 5 Allophycocyanin (APC)-labeled vascular endothelial growth factor (VEGF, final concentration 3 μg / mL) and umbilical cord blood mononuclear cells (containing 1×10 4 The co-culture experiment was carried out under the condition of 1:1 CD34 positive cells (cell number). Figure 5 The left side shows the correlation between the expression of connexin43 in hematopoietic stem cells (CD34 positive, CD45 positive, and 7AAD negative) and the VEGF uptake ability of HUVEC in the co-culture experiment. It was found that the expression intensity of connexin43, which is an indicator of promoting VEGF uptake ability, is useful as a marker for selecting monocytes with high therapeutic effects.

[0125] (5) CD18 expression in cord blood mononuclear cells before freezing and after freezing and thawing

[0126] In fact, the CD18 expression of umbilical cord blood mononuclear cells before freezing and after freezing and thawing was studied. The results showed that, similar to the case of heparin treatment, there were cases where the expression was significantly reduced and cases where it was almost unchanged. The former was a case of high expression of CD18, and the latter was a case of low expression ( Figure 6 ).

[0127] Specifically, a mononuclear cell fraction was separated from the umbilical cord blood by the above-mentioned Ficoll-Paque specific gravity centrifugation method, and the mononuclear cell fraction was aliquoted.

[0128] A portion of the mononuclear cell fraction was stained with PE-labeled anti-human CD34 antibody, 7AAD, FITC-labeled anti-human CD45 antibody, and APC-labeled CD18 antibody, and the expression level of CD18 antigen in hematopoietic stem cells (CD34 positive, CD45 positive, and 7AAD negative) was evaluated using a FACS Canto II cell analyzer (BD Bioscience).

[0129] Next, a cryoprotectant (Cell Banker) was added to the remaining mononuclear cell fraction, frozen in a program freezer and stored in liquid nitrogen. One week later, the cryopreserved mononuclear cells were thawed and the expression level of CD18 antigen in hematopoietic stem cells was evaluated in the same manner as above.

[0130] like Figure 6 As shown, the expression of CD18 by umbilical cord blood mononuclear cells with high CD18 expression before freezing and after freezing and thawing was significantly reduced, while the expression of CD18 by umbilical cord blood mononuclear cells with low CD18 expression before freezing and after freezing and thawing remained at a low level.

[0131] Next, in order to further verify the usefulness of CD18-positive cells, the following study was performed.

[0132] (6) Collection of CD18-positive cells

[0133] The cell recovery method with high therapeutic effect in the present invention has the following steps. That is: a collection step of collecting human bone marrow fluid using a diluent that does not contain heparin, and a separation step of adding a gravity centrifuge that does not contain heparin to the collected human bone marrow fluid and performing gravity centrifugation. In this embodiment, it is specifically described as follows. 2ml of normal saline and a 23G injection needle are set in a 2.5ml syringe. Cut both ends of the mouse femur with surgical scissors, insert the injection needle into one end of the bone marrow cavity, and quickly inject normal saline to obtain bone marrow fluid flowing out from the other end. Normally, bone marrow fluid is easy to coagulate, so anticoagulants such as heparin are mostly used, but heparin is not used in the present invention, and the coagulation of the bone marrow fluid is only inhibited by dilution with normal saline.

[0134] The bone marrow fluid diluted with physiological saline to inhibit coagulation was superimposed on a gravity centrifuge (Ficoll-premium manufactured by GE), and the mixture was centrifuged at 600 g for 20 minutes, and the cell population present in the buffy coat was recovered.

[0135] (7) Determination of CD18-positive cells

[0136] After the cell population was collected, surface marker analysis was performed by FACS (BD FACSCalibur) using an anti-CD18 antibody.

[0137] Dead cells were excluded from the analysis using 7AAD (7-Amino-actinomycin D; manufactured by BD Bioscience, product number 559925, dilution factor: 50-fold). As a negative control, respective isotype controls were used.

[0138] As a characteristic of the cell population, analysis based on flow cytometry confirmed that more than 90% of the cells expressed the CD18 antigen ( Figure 7 ). Analysis based on flow cytometry is an analysis in which an antibody is fluorescently labeled directly or indirectly, a target cell population is measured using a flow cytometer, and the proportion of cells showing a positive reaction is calculated. A positive reaction based on flow cytometry means that the fluorescence intensity of the unique wavelength emitted by the fluorescent dye used for labeling is included in a fluorescence region with a higher intensity than the background intensity measured without using the primary antibody.

[0139] Similarly, after the cell population was collected, surface marker analysis was performed using FACS (BD FACSCalibur) using anti-Jagged1 antibody. Figure 8Therefore, in order to study the regeneration-promoting effect of Jagged1 molecules, Jagged1 peptide (H-Cys-Asp-Asp-Tyr-Tyr-Tyr-Gly-Phe-Gly-Cys-Asn-Lys-Phe-Cys-Arg-Pro-Arg-OH) with Jagged1 activity was added to the culture medium of HUVEC to study its effect of promoting VEGF uptake.

[0140] The results showed that without stimulation, 1.04% of HUVECs took up VEGF, while under the stimulation of Jagged1, 5.30% of HUVECs took up VEGF ( Fig. 9 ) These results confirmed that the expression of Jagged1 in stem cells is important for the regeneration-promoting effect.

[0141] (8) Administration of CD18-positive cells to aged mice

[0142] 1×10 5 Each of the above cells was suspended in 100 μl of PBS and administered to CB-17 mice (aged mice) aged 80 weeks or older through the tail vein once every other day for a total of 5 times. The same amount of PBS was intravenously injected into the control group.

[0143] 24 hours after the last intravenous administration, the brain was removed and fixed with 2% paraformaldehyde, sliced ​​into 20 μm thick sections using a vibrating microtome (manufactured by Leica), and stained with anti-Nestin antibody (manufactured by Merck Millipore, product number MAB5326, dilution ratio 1:200), anti-Doublecortin antibody (DCX; manufactured by Merck Millipore, product number AB2253, dilution ratio 1:350) and nuclear staining DAPI (manufactured by Thermo Fisher, product number D1306, dilution ratio 1:1,000) (mice administered with CD18 cells: 7 mice, total 22 slices; mice administered with PBS: 6 mice, total 20 slices).

[0144] Confocal images were taken using a fluorescence microscope (BZ-X810) manufactured by Keyence to evaluate the number of newborn neuron marker (Nestin)-positive cells in the granule cell layer of the hippocampal dentate gyrus and the number of newborn neuron (DCX)-positive cells in the granule cell layer. In order to quantitatively evaluate the effect of administering CD18-positive cells, the number of cells positive for each newborn neuron marker was counted, and the results showed that the number of Nestin-positive cells ( Fig.10 A) and DCX-positive cells ( Fig.10B) Both were statistically significantly increased.

[0145] In patients with diseases accompanied by neurological dysfunction caused by aging, neurogenesis in the hippocampus is impaired, but according to the present invention, neurogenesis in the hippocampus can be promoted, and the above-mentioned diseases can be prevented and / or treated. Even in the case of decreased neurological function caused by aging, according to the present invention, neurogenesis in the hippocampus can be promoted, thereby improving aging and also delaying aging.

[0146] Industrial Applicability

[0147] It can be used to treat cerebral infarction or neurological disorders caused by aging.

Claims

1. A cell preparation, It is characterized in that Contains CD18 positive cells.

2. The cell preparation according to claim 1, It is characterized in that The CD18-positive cells express the glucose transporter, Glut.

3. The cell preparation according to claim 2, It is characterized in that The glucose transporter is a type I glucose transporter, namely Glut1.

4. The cell preparation according to claim 1, It is characterized in that The CD18-positive cells express connexin.

5. The cell preparation according to claim 4, It is characterized in that The connexin is connexin 43, namely Connexin43.

6. The cell preparation according to claim 1, It is characterized in that The CD18-positive cells express Jagged1.

7. The cell preparation according to claim 1, It is characterized in that The CD18-positive cells express the glucose transporter Glut1 and the connexin 43.

8. The cell preparation according to claim 1, It is characterized in that The CD18-positive cells express the glucose transporter Glut1, Connexin43 and Jagged1.

9. The cell preparation according to claim 1, It is characterized in that The CD18 positive cells are stem cells.

10. The cell preparation according to claim 9, It is characterized in that The stem cells are adult stem cells.

11. The cell preparation according to claim 10, It is characterized in that The adult stem cells are hematopoietic stem cells.

12. The cell preparation according to claim 11, It is characterized in that The hematopoietic stem cells are CD34 positive bone marrow mononuclear cells.

13. The cell preparation according to claim 11, It is characterized in that The hematopoietic stem cells are CD34 positive umbilical cord blood mononuclear cells.

14. The cell preparation according to any one of claims 1 to 13, It is characterized in that The cell preparation is a brain function improver, a brain metabolism activator, a brain circulation improver, a neurotransmission function improver, a brain protector or a memory disorder improver.

15. The cell preparation according to any one of claims 1 to 14, It is characterized in that The CD18-positive cells are a cell population in which the proportion of cells showing CD18-positive reaction is 90% or more when analyzed by flow cytometry.

16. A neurogenesis promoter in the hippocampus, It is characterized in that Contains CD18 positive cells.

17. The neurogenesis promoting agent according to claim 16, It is characterized in that The hippocampus is the dentate gyrus of the hippocampus.

18. The neurogenesis promoting agent according to claim 16 or 17, It is characterized in that The CD18 positive cells are connexin43 positive.

19. The neurogenesis promoting agent according to claim 18, It is characterized in that The CD18-positive cells are a cell population in which the proportion of cells showing a connexin 43-positive reaction is 60% or more when analyzed by flow cytometry.

20. The neurogenesis promoting agent according to any one of claims 16 to 19, It is characterized in that Used to prevent and / or treat decreased neurological function due to aging.

21. The neurogenesis promoting agent according to any one of claims 16 to 19, It is characterized in that For use in preventing and / or treating diseases associated with neurological dysfunction due to aging.

22. The neurogenesis promoting agent according to any one of claims 16 to 19, It is characterized in that For the prevention and / or treatment of mental illness.

23. The neurogenesis promoting agent according to claim 22, It is characterized in that The mental illness is any one selected from depression, schizophrenia, bipolar disorder or autism spectrum disorder.

24. The neurogenesis promoting agent according to any one of claims 16 to 19, It is characterized in that For the prevention and / or treatment of dementia.

25. The neurogenesis promoting agent according to claim 24, in, The dementia is any neurodegenerative disease selected from Alzheimer's disease, Lewy body dementia, frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy or Parkinson's disease.

26. A cell recovery method, It is characterized in that The cell recovery method collects human bone marrow fluid and separates a cell population from the human bone marrow fluid by specific gravity centrifugation. The cell recovery method has the following steps: A collection process, using a diluent not containing heparin to collect human bone marrow fluid; and In the separation step, a gravity centrifuge fluid not containing heparin is added to the collected human bone marrow fluid, and gravity centrifugation is performed.